Johannes Weller, Niklas Schäfer, Christina Schaub, Anna-Laura Potthoff, Joachim Peter Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Clemens Seidel, Dietmar Krex, Roland Goldbrunner, Torsten Pietsch, Theophilos-Dimitrios Tzaridis, Thomas Zeyen, Valeri Borger, Erdem Özer Güresir, Hartmut Vatter, Ulrich Herrlinger, Matthias Schneider
- Purpose: The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy.
Methods: The impact of obesity (BMI ≥ 30 kg/m2) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan–Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables.
Results: Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7–30.8) vs. 43.2 (32.5–54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8–18.9) vs 17.6 (14.7–20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53–4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm.
Conclusion: Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.
MetadatenVerfasserangaben: | Johannes WellerORCiD, Niklas SchäferGND, Christina SchaubGND, Anna-Laura PotthoffORCiDGND, Joachim Peter SteinbachORCiDGND, Uwe SchlegelGND, Michael SabelORCiDGND, Peter HauORCiDGND, Clemens SeidelGND, Dietmar KrexGND, Roland GoldbrunnerORCiDGND, Torsten PietschORCiD, Theophilos-Dimitrios TzaridisORCiDGND, Thomas ZeyenGND, Valeri BorgerGND, Erdem Özer GüresirORCiDGND, Hartmut VatterORCiDGND, Ulrich HerrlingerORCiDGND, Matthias SchneiderORCiD |
---|
URN: | urn:nbn:de:hebis:30:3-694589 |
---|
DOI: | https://doi.org/10.1007/s11060-022-04046-z |
---|
ISSN: | 1573-7373 |
---|
Titel des übergeordneten Werkes (Englisch): | Journal of neuro-oncology |
---|
Verlag: | Springer Science + Business Media B.V |
---|
Verlagsort: | Dordrecht [u.a.] |
---|
Dokumentart: | Wissenschaftlicher Artikel |
---|
Sprache: | Englisch |
---|
Datum der Veröffentlichung (online): | 15.06.2022 |
---|
Datum der Erstveröffentlichung: | 15.06.2022 |
---|
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Datum der Freischaltung: | 20.02.2023 |
---|
Freies Schlagwort / Tag: | Glioblastoma; MGMT; Obesity; Temozolomide |
---|
Jahrgang: | 159 |
---|
Ausgabe / Heft: | 1 |
---|
Seitenzahl: | 7 |
---|
Erste Seite: | 95 |
---|
Letzte Seite: | 101 |
---|
Bemerkung: | The involved trials were supported by the German Ministry for Education and Science (CeTeG/NOA-09 [10]), Roche (GLARIUS [12]) and Bundesministerium für Bildung und Forschung (Grant No. 01KG1005). Open Access funding enabled and organized by Projekt DEAL. |
---|
HeBIS-PPN: | 507154770 |
---|
Institute: | Medizin |
---|
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Lizenz (Deutsch): | Creative Commons - CC BY - Namensnennung 4.0 International |
---|